ArticleEcancermedicalscience2014
Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.
Article in Ecancermedicalscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Itraconazole as a repurposed anti-cancer agent: focusing on synthesis, mechanisms of action and therapeutic insights.RSC advances · 2026Review
- Association Between Long-term Use of HJournal of Cancer · 2026Article
- NanoDSF Screening for Anti-tubulin Agents Uncovers New Structure-Activity Insights.Journal of medicinal chemistry · 2025Article
- Comparative and pharmacological investigation of bEVs from eight Lactobacillales strains.Scientific reports · 2025Article
- Review
- Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance.Genes & diseases · 2024Review
- Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials.Cancers · 2023Review
- Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates.Oncotarget · 2022Review
- The effect of medications associated with drug-induced pancreatitis on pancreatic cancer risk: A nested case-control study of routine Scottish data.Cancer epidemiology · 2021Article
- Research Supporting a Pilot Study of Metronomic Dapsone during Glioblastoma Chemoirradiation.Medical sciences (Basel, Switzerland) · 2021Article
- Article
- Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer.International journal of molecular sciences · 2019Review
- Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- Vitamin BFrontiers in endocrinology · 2019Article
- β2ARs stimulation in osteoblasts promotes breast cancer cell adhesion to bone marrow endothelial cells in an IL-1β and selectin-dependent manner.Journal of bone oncology · 2018Article
- Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.Ecancermedicalscience · 2018Article
- Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.JAMA oncology · 2017Article
- Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?Molecules (Basel, Switzerland) · 2016Review
- Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Ecancermedicalscience · 2016Article
- Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.Ecancermedicalscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.